Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503)

Overview

Journal Anticancer Res

Specialty Oncology

Date 2008 Aug 30

PMID 18751370

Citations 46

Authors

Dietmar W Siemann

Wenyin Shi

Affiliations

Soon will be listed here.

Abstract

Background: This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents.

Materials And Methods: Human clear cell renal carcinoma (Caki-1) tumors were established in nude mice. Treatments consisted of Avastin (2 mg/kg) administered twice a week; CA4P (100 mg/kg) or OXi4503 (25 mg/kg) administered 3 times a week for a period of 2 weeks; or a combination of Avastin and CA4P or OXi4503. Tumor response was assessed by growth delay.

Results: The tumor growth delays were 8, 6, and 18 days for Avastin, CA4P, and OXi4503, respectively. When the two therapies were combined, there was a significantly greater tumor response than what was achieved with single-agent treatments. For example, Avastin plus CA4P led to a growth delay of 13 days, and 27 days for Avastin plus OXi4503.

Conclusion: Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.

Citing Articles

Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice.

Wanniarachchi H, Schuetze R, Deng Y, Hamal K, Pavlich C, Tankoano P Cancers (Basel). 2025; 17(5).

PMID: 40075618 PMC: 11898701. DOI: 10.3390/cancers17050771.

Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.

Horsman M Int J Mol Sci. 2024; 25(15).

PMID: 39125647 PMC: 11311563. DOI: 10.3390/ijms25158078.

Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy.

Sidorenko V, Scodeller P, Uustare A, Ogibalov I, Tasa A, Tshubrik O Sci Rep. 2024; 14(1):17513.

PMID: 39080306 PMC: 11289491. DOI: 10.1038/s41598-024-64610-7.

Multi-parametric investigations on the effects of vascular disrupting agents based on a platform of chorioallantoic membrane of chick embryos.

Chen L, Wang M, Feng Y, Gao L, Yu J, Geng L Quant Imaging Med Surg. 2024; 14(2):1729-1746.

PMID: 38415159 PMC: 10895113. DOI: 10.21037/qims-23-1065.

Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment.

Liu L, Schuetze R, Gerberich J, Lopez R, Odutola S, Tanpure R Cancers (Basel). 2022; 14(17).

PMID: 36077745 PMC: 9454770. DOI: 10.3390/cancers14174208.

References

Vaupel P, Kallinowski F, Okunieff P . Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989; 49(23):6449-65. View

Hua J, Sheng Y, Pinney K, Garner C, Kane R, Prezioso J . Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003; 23(2B):1433-40. View

Rojiani A, Li L, Rise L, Siemann D . Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncol. 2002; 41(1):98-105. DOI: 10.1080/028418602317314136. View

Tozer G, Kanthou C, Baguley B . Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5(6):423-35. DOI: 10.1038/nrc1628. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Salmon B, Siemann D . Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys. 2007; 68(1):211-7. PMC: 1868579. DOI: 10.1016/j.ijrobp.2006.12.051. View

Herbst R, Arquette M, Shin D, Dicke K, Vokes E, Azarnia N . Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005; 23(24):5578-87. DOI: 10.1200/JCO.2005.07.120. View

Siemann D, Bibby M, Dark G, Dicker A, Eskens F, Horsman M . Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005; 11(2 Pt 1):416-20. View

Li L, Rojiani A, Siemann D . Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol. 2002; 41(1):91-7. DOI: 10.1080/028418602317314127. View

10.

Johnson D, Fehrenbacher L, Novotny W, Herbst R, Nemunaitis J, Jablons D . Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22(11):2184-91. DOI: 10.1200/JCO.2004.11.022. View

11.

Hill S, Toze G, Pettit G, Chaplin D . Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 2002; 22(3):1453-8. View

12.

Siemann D, Horsman M . Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther. 2004; 4(2):321-7. DOI: 10.1586/14737140.4.2.321. View

13.

Pettit G, Singh S, Hamel E, Lin C, Alberts D . Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989; 45(2):209-11. DOI: 10.1007/BF01954881. View

14.

Gerber H, Ferrara N . Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005; 65(3):671-80. View

15.

Siemann D, Chaplin D, Horsman M . Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004; 100(12):2491-9. DOI: 10.1002/cncr.20299. View

16.

Shi W, Siemann D . Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo. 2005; 19(6):1045-50. View

17.

DAdamo D, Anderson S, Albritton K, Yamada J, Riedel E, Scheu K . Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005; 23(28):7135-42. DOI: 10.1200/JCO.2005.16.139. View

18.

Sheng Y, Hua J, Pinney K, Garner C, Kane R, Prezioso J . Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer. 2004; 111(4):604-10. DOI: 10.1002/ijc.20297. View

19.

Folkman J . How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res. 1986; 46(2):467-73. View

20.

Miller K, Chap L, Holmes F, Cobleigh M, Marcom P, Fehrenbacher L . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005; 23(4):792-9. DOI: 10.1200/JCO.2005.05.098. View